Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges.

Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its full Annual Report 2023. Dermapharm confirms its preliminary consolidated figures (IFRS) for financial year 2023.

Grünwald, 14 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its unaudited preliminary consolidated figures (IFRS) for financial year 2023. The Group increased revenue by 10.8% to EUR 1,135.4 million in the reporting period (prior-year period: EUR 1,024.8 million).

Grünwald, 15 November 2023 – Dermapharm Holding SE ("Dermapharm"), an innovative rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its results for the first nine months of 2023.

Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its report for the first half of 2023 and confirmed the preliminary consolidated figures (IFRS).

Grünwald, 16 August 2023 – Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its unaudited preliminary consolidated figures (IFRS) for the first half of 2023. In the first six months of financial year 2023, the Company lifts its revenue by 24% to EUR 582 million (prior-year period: EUR 471 million).

Grünwald, 14 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2023 Annual General Meeting. 22.53% of the share capital was in attendance at the Annual General Meeting, which was held in person. The majority of shareholders approved the management's proposals under every agenda item.

Grünwald, 13 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, contractually acquired a significant interest in Pharmazeutische Fabrik Montavit Gesellschaft m.b.H. ("Montavit"), Absam, Tyrol, Austria, via its wholly owned subsidiary Dermapharm AG on 7 June 2023.

Grünwald, 22. März 2023 - At its meeting today, the Board of Management of Dermapharm Holding SE resolved to propose to the Company's Annual General Meeting, which is exxpected to be held on 14 June 2023, the distribution of a dividend for the 2022 financiel year amounting to EUR 1.05 per no-par value share carrying dividend rights (previous year: EUR 2.17 per share).

Grünwald, 14 March 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its unaudited preliminary consolidated figures (IFRS) for financial year 2022. Despite the difficult macroeconomic environment, Dermapharm succeeded in maintaining its growth trajectory.